Table 4 Factors associated with receiving treatment among HPV positive, triage positive women in Nicaragua in 2017
From: HPV-based cervical cancer screening in Nicaragua: from testing to treatment
Not treated (N = 429) | Treated (N = 486) | ||||
|---|---|---|---|---|---|
n (%) | n (%) | Unadjusted Prevalence ORa (95%CI) | Adjusted Prevalence ORb (95%CI) | Treatment Ratio | |
Province | |||||
Carazo | 50 (29.2) | 121 (70.7) | Ref | Ref | Ref |
Chinandega | 199 (70.1) | 85 (29.9) | 0.18 (0.12–0.27)* | 0.34 (0.20–0.56)* | 0.42 |
Chontales | 180 (39.1) | 280 (60.9) | 0.64 (0.44–0.94)** | 0.67 (0.42–1.07) | 0.86 |
Age, years | |||||
< 30 | 5 (55.6) | 4 (44.4) | Ref | Ref | Ref |
30–39 | 247 (44.3) | 311 (55.7) | 1.57 (0.42–5.92) | 1.26 (0.21–7.77) | 1.25 |
40–49 | 102 (46.4) | 118 (53.6) | 1.44 (0.38–5.52) | 1.37 (0.22–8.59) | 1.21 |
50–59 | 71 (57.3) | 53 (42.7) | 0.93 (0.24–3.64) | 1.13 (0.18–7.27) | 0.96 |
60+ | 4 (100.0) | 0 (0) | NA | NA | NA |
Unknown | |||||
HPV Screening Modality | |||||
Self-collected | 420 (46.8) | 477 (53.2) | Ref | Ref | Ref |
Provider-collected | 9 (52.9) | 8 (47.1) | 0.78 (0.30–2.04) | 1.11 (0.37–3.32) | 0.89 |
Unknown | 0 (0) | 1 (100.0) | NA | NA | 1.88 |
Triage Method | |||||
VIA | 48 (11.9) | 354 (88.1) | Ref | Ref | Ref |
Pap | 381 (74.3) | 132 (25.7) | 0.05 (0.03–0.07)* | 0.05 (0.04–0.08)* | 0.29 |